Publications by authors named "L E Hendriks"
This review discusses the current data on predictive and prognostic biomarkers in oligometastatic NSCLC and discusses whether biomarkers identified in other stages and widespread metastatic disease can be extrapolated to the oligometastatic disease (OMD) setting. Research is underway to explore the prognostic and predictive value of biological attributes of tumor tissue, circulating cells, the tumor microenvironment, and imaging findings as biomarkers of oligometastatic NSCLC. Biomarkers that help define true OMD and predict outcomes are needed for patient selection for oligometastatic treatment, and to avoid futile treatments in patients that will not benefit from locoregional treatment.
View Article and Find Full Text PDFIntroduction: The EORTC-Lung Cancer Group initiated a Delphi consensus process to establish a consensual definition of resectable stage III non-small cell lung cancer (NSCLC) for the use in clinical trials, including a systematic review, survey, and review of clinical cases. Here, the survey results are presented, aimed to identify areas of controversy.
Methods: A survey was distributed among the members of six international organizations related to lung cancer.
Patient perspectives on treatment-related toxicities and therapeutic drug monitoring with tyrosine kinase inhibitors for the treatment of non-small-cell lung cancer.
Ther Adv Med Oncol
December 2024
Background: Tyrosine kinase inhibitors (TKIs) have significantly improved treatment-related outcomes of patients with oncogene-driven non-small-cell lung cancer (NSCLC). TKIs are usually well tolerated and used for a prolonged time, although experienced toxicity varies between patients. It is unclear whether patients report all (low grade) toxicities and how these impact their daily lives.
View Article and Find Full Text PDFArticle Synopsis
- Alectinib is a treatment for ALK+ non-small cell lung cancer, but many patients experience drug-related toxicity requiring dose adjustments, potentially linked to genetic variants.
- In a study of 215 patients, 47% had severe toxicity, with females being more affected and having higher drug levels. Additionally, specific genetic variants like PPAR-α 209G>A were associated with increased toxicity.
- Identifying these genetic factors could help tailor treatments and reduce adverse effects, suggesting the need for pre-treatment genetic testing and possible dose modifications.
Background: Cognitive decline is an arising concern in patients who need cranial irradiation. We used the pooled longitudinal individual patient data of two phase III trials: NCT01780675 and PREMER to investigate whether hippocampal avoidance (HA)-PCI is associated with improved self-reported cognitive functioning (SRCF) compared with PCI without increasing brain metastases (BM) development within the HA area.
Methods: Patients with stage I-IV small cell lung cancer (SCLC) were randomized to PCI or HA-PCI.